# Indonesia Generic Pharmaceuticals Market Size, Share & Forecast, By Product Type, Therapeutic Area & Distribution Channel, 2026–2031 --- ## Market Overview # CHAPTER 1 - Market Overview The Indonesia Generic Pharmaceuticals Market operates through JKN formulary demand, private prescriptions, hospital procurement, and retail pharmacy substitution. JKN covered 282.7 million people, equal to 98.62% of Indonesia’s population, and recorded 725.3 million service uses in 2025. This scale creates recurring volume for cost-efficient chronic and acute therapies, while rewarding suppliers that can sustain tender prices, availability, and nationwide fulfillment. Commercial activity is concentrated in Java, particularly Jakarta, Bandung, and Surabaya, where manufacturers, tertiary hospitals, wholesalers, and high-volume pharmacies cluster. Indonesia had 219 finished-dose pharmaceutical manufacturers, including 209 chemical-drug producers, 7 biosimilar producers, and 3 vaccine producers. This installed base supports shorter replenishment cycles and portfolio breadth, although distribution economics remain more difficult outside the principal urban corridors. Regulatory access depends on BPOM registration, bioequivalence evidence, CPOB compliance, national formulary inclusion, and procurement eligibility. BPOM completed review of 915 expired generic product licenses in under three months, issuing 769 renewals and declining or cancelling 146 applications. Faster renewal can protect JKN continuity, but the 16% non-approval outcome reinforces the commercial cost of weak dossiers, testing gaps, and quality-system deficiencies. Indonesia’s strategic transition is toward greater input self-sufficiency, yet approximately 90% of pharmaceutical raw materials have historically been imported and only 18 active pharmaceutical ingredient manufacturers were certified in the latest BPOM facility count. Import exposure links generic margins to currency, freight, and global supply disruptions, making local API partnerships, dual sourcing, and formulation redesign central to investor and operator resilience. ## KPIs at a Glance * Market Value: USD 4,400 million (2025) * Dominant Region: Java (2025) * Dominant Segment: Simple Generics (dominant); Biosimilars (fastest growing) * Total Number of Players: 219 ## Future Outlook The Indonesia Generic Pharmaceuticals Market is projected to expand from USD 4,400 Mn in 2025 to USD 6,750 Mn by 2031, representing a forecast CAGR of 7.4%. The outlook is underpinned by near-universal insurance coverage, a chronic-disease burden of 20.4 million adults with diabetes, and continued use of formulary-based procurement to control treatment costs. Historical growth averaged 7.6% during 2020-2025, indicating that the market has already established a durable demand base rather than relying on a single policy cycle. Growth should remain volume-led, with selective pricing uplift in specialty generics, complex formulations, and biosimilars. Profit pools are expected to migrate from highly commoditized oral solids toward differentiated hospital products, chronic therapies, contract manufacturing, and digitally enabled distribution. Manufacturers with reliable BPOM renewal performance, domestic sourcing, and strong hospital tender execution should outperform. Online pharmacy participation is modeled to rise from 3.0% of generic sales in 2025 to 8.0% by 2031 as internet access broadens, while biosimilar capability benefits from the existing base of seven certified producers. Strategic risks remain reimbursement-price mismatch, delayed payments, and imported API exposure, which can compress margins despite revenue growth. --- | | | | --- | --- | | **7.4%** Forecast CAGR | **$6,750 Mn** 2031 Projection | --- | | | | | | --- | --- | --- | --- | | Base Year **2025** | Historical Period **2020-2025** | Forecast Period **2026-2031** | Historical CAGR **7.6%** | --- ## Scope of the Report # CHAPTER 2 - Scope of the Market * **Geographic Coverage:** Indonesia * **Historical Period:** 2020-2025 * **Base Year:** 2025 * **Forecast Period:** 2026-2031 * **Market Segments Covered:** 7 primary segmentation dimensions (Product Type, Therapeutic Area, Formulation and Drug Delivery, Care Setting, End User, Distribution Channel, Geography) * **Companies Covered:** Top 10 key players profiled * **Currency & Units:** USD, values expressed in USD Mn/Bn ### Segmentation Data Tree * Product Type + Simple Generics - Immediate-release tablets - Standard hard-gel capsules + Specialty Generics - High-potency therapies - Narrow-therapeutic-index products + Complex Generics - Long-acting injectables - Complex topical formulations + Biosimilars - Insulin biosimilars - Monoclonal antibody biosimilars * Therapeutic Area + Cardiovascular - Antihypertensives - Lipid-lowering agents + Anti-Infectives - Systemic antibiotics - Antiviral therapies + Endocrine and Metabolic - Diabetes therapies - Thyroid and metabolic therapies + Other Therapeutic Areas - Central nervous system products - Oncology and respiratory products * Formulation and Drug Delivery + Oral - Tablets - Capsules + Injectables - Small-molecule injectables - Biologic injectables + Dermal and Topical - Creams and ointments - Transdermal preparations + Inhalation - Metered-dose inhalers - Dry-powder inhalers * Care Setting + Hospitals - Public hospitals - Private hospitals + Primary Care Facilities - Puskesmas - Primary clinics + Specialist Clinics - Diabetes clinics - Oncology and cardiac clinics + Home-Based Care - Chronic refill programs - Caregiver-supported therapy * End User + Public Health Providers - JKN-contracted hospitals - Government primary care providers + Private Hospitals and Clinics - Private hospital groups - Independent specialist clinics + Retail Pharmacies - National pharmacy chains - Independent pharmacies + Patients and Caregivers - Chronic-disease patients - Family caregivers * Distribution Channel + Hospital Pharmacies - Inpatient dispensing - Outpatient dispensing + Retail Pharmacies - Chain pharmacy sales - Independent pharmacy sales + Government E-Procurement - National e-catalogue tenders - Facility-level procurement + Online Pharmacies - Platform pharmacies - Omnichannel pharmacy fulfillment * Geography + Java - Jakarta metropolitan area - West, Central, and East Java + Sumatra - Northern Sumatra - Southern Sumatra + Kalimantan - Western and Central Kalimantan - Eastern and Southern Kalimantan + Eastern Indonesia - Sulawesi and Bali-Nusa Tenggara - Maluku and Papua --- ## Market Trajectory # CHAPTER 3 - Market Size, Growth Forecast and Trends This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers. ### Historical and Projected Market Size (USD Mn) | Year | Market Size (USD Mn) | | --- | --- | | 2020 | 3,050 | | 2021 | 3,290 | | 2022 | 3,540 | | 2023 | 3,810 | | 2024 | 4,100 | | 2025 | 4,400 | | 2026F | 4,725 | | 2027F | 5,075 | | 2028F | 5,450 | | 2029F | 5,853 | | 2030F | 6,286 | | 2031F | 6,750 | ### YoY Growth Rate (%) | Year | YoY Growth (%) | | --- | --- | | 2021 | 7.9% | | 2022 | 7.6% | | 2023 | 7.6% | | 2024 | 7.6% | | 2025 | 7.3% | | 2026F | 7.4% | | 2027F | 7.4% | | 2028F | 7.4% | | 2029F | 7.4% | | 2030F | 7.4% | | 2031F | 7.4% | ### Market Value vs Volume Growth (%) | Year | Market Value Growth (%) | Generic Volume Growth (%) | | --- | --- | --- | | 2020 | - | - | | 2021 | 7.9% | 1.3% | | 2022 | 7.6% | 1.5% | | 2023 | 7.6% | 1.7% | | 2024 | 7.6% | 1.6% | | 2025 | 7.3% | 1.9% | | 2026 | 7.4% | 2.0% | | 2027 | 7.4% | 2.1% | | 2028 | 7.4% | 2.2% | | 2029 | 7.4% | 2.2% | | 2030 | 7.4% | 2.3% | ### Historical Market Performance (2020-2025) Historical performance was resilient, with the market increasing by USD 1,350 Mn across 2020-2025 and recording its strongest annual expansion of 7.9% in 2021. The subsequent growth band remained narrow at 7.3%-7.6%, signaling stable reimbursement-led demand rather than a short-lived recovery spike. Volume growth accelerated from 1.3% in 2021 to 1.9% in 2025, while value growth remained higher, reflecting therapy-mix upgrading, distribution costs, and greater contribution from branded and specialty generics. Demand concentration strengthened around chronic-care prescriptions and public procurement, reducing sensitivity to discretionary consumer spending. ### Forecast Market Outlook (2026-2031) The forecast maintains a 7.4% CAGR, adding USD 2,350 Mn of annual market value between 2025 and 2031. Terminal growth remains supported by JKN utilization, chronic disease prevalence, and increasing participation of complex generics and biosimilars. Generic volume growth is projected to rise from 2.0% in 2026 to 2.3% in 2030, while value growth remains faster because product mix and channel economics outweigh pure unit expansion. The projected 2031 scale assumes continued formulary prioritization, improved registration throughput, and measured growth in online pharmacy fulfillment without a material deterioration in public reimbursement or medicine availability. --- ## Market Breakdown # CHAPTER 4 - Market Breakdown The Indonesia Generic Pharmaceuticals Market combines stable reimbursement demand with an evolving product and channel mix. For CEOs and investors, the central issue is not only top-line growth, but whether portfolio differentiation and procurement execution can offset price pressure in commodity generics. | Year | Market Size (USD Mn) | YoY Growth (%) | Generic Volume Share (Modeled %) | Chronic Therapy Share (Modeled %) | Online Pharmacy Share (Modeled %) | Period | | --- | --- | --- | --- | --- | --- | --- | | 2020 | 3,050 | - | 72.0% | 38.0% | 1.2% | Historical | | 2021 | 3,290 | 7.9% | 73.0% | 39.0% | 1.5% | Historical | | 2022 | 3,540 | 7.6% | 74.0% | 40.0% | 1.8% | Historical | | 2023 | 3,810 | 7.6% | 75.3% | 41.0% | 2.2% | Historical | | 2024 | 4,100 | 7.6% | 76.7% | 42.0% | 2.6% | Historical | | 2025 | 4,400 | 7.3% | 77.5% | 43.0% | 3.0% | Base Year | | 2026 | 4,725 | 7.4% | 78.3% | 44.0% | 3.6% | Forecast and Latest Operating KPIs | | 2027 | 5,075 | 7.4% | 79.0% | 45.0% | 4.3% | Forecast and Industry Outlook | | 2028 | 5,450 | 7.4% | 79.7% | 46.0% | 5.1% | Forecast and Industry Outlook | | 2029 | 5,853 | 7.4% | 80.4% | 47.0% | 6.0% | Forecast and Industry Outlook | | 2030 | 6,286 | 7.4% | 81.2% | 48.0% | 7.0% | Forecast and Industry Outlook | | 2031 | 6,750 | 7.4% | 82.0% | 49.0% | 8.0% | Forecast and Industry Outlook | **KPI 1, Generic Volume Share:** **76.7% (2024, Indonesia)**. High unit penetration makes price realization, supply continuity, and mix management more important than simple prescription capture. Public evidence indicates generics already represent the majority of pharmaceutical volume, supporting a structurally mature substitution base. **KPI 2, Chronic Therapy Share:** **43.0% (2025, Indonesia)**. Chronic portfolios offer repeat dispensing and stronger demand visibility, favoring companies with cardiovascular and diabetes breadth. Indonesia recorded **20.4 million adults with diabetes (2024, Indonesia)**, creating a durable refill pool. **KPI 3, Online Pharmacy Share:** **3.0% (2025, Indonesia)**. Digital channels remain small but increasingly relevant for refill adherence and metropolitan reach. Internet penetration reached **79.5% (2024, Indonesia)**, giving omnichannel pharmacy operators a broad addressable user base. --- --- ## Market Segmentation # CHAPTER 5 - Market Segmentation Framework Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns. | | | | | --- | --- | --- | | **No of Segments:** 7 | **Dominant Segment:** Product Type | **Fastest Growing Segment:** Distribution Channel | ### Segmentation Framework | Priority | Level-1 Segment / Taxonomy Dimension | Level-2 Sub-Segments | | --- | --- | --- | | 1 | Product Type | Simple Generics; Specialty Generics; Complex Generics; Biosimilars | | 2 | Therapeutic Area | Cardiovascular; Anti-Infectives; Endocrine and Metabolic; Other Therapeutic Areas | | 3 | Formulation and Drug Delivery | Oral; Injectables; Dermal and Topical; Inhalation | | 4 | Care Setting | Hospitals; Primary Care Facilities; Specialist Clinics; Home-Based Care | | 5 | End User | Public Health Providers; Private Hospitals and Clinics; Retail Pharmacies; Patients and Caregivers | | 6 | Distribution Channel | Hospital Pharmacies; Retail Pharmacies; Government E-Procurement; Online Pharmacies | | 7 | Geography | Java; Sumatra; Kalimantan; Eastern Indonesia | ### Key Segmentation Takeaways Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns. **Product Type** - Simple Generics remain the commercial anchor because they align with JKN price controls, high-volume formulary prescribing, and broad manufacturing capability. Immediate-release tablets and standard capsules account for the widest set of essential medicines and support high plant utilization. Specialty, complex, and biosimilar products are smaller but provide stronger differentiation, more defensible hospital relationships, and improved margin potential where regulatory and technical capabilities are available. **Distribution Channel** - Government E-Procurement and hospital pharmacies retain scale, but Online Pharmacies are the fastest-growing channel because chronic refill behavior, digital payments, and omnichannel fulfillment reduce transaction friction. Retail pharmacies remain critical for nationwide access and substitution advice. The strongest operators will integrate e-catalogue execution, hospital inventory planning, wholesale distribution, and patient-facing digital channels rather than treating each route as an isolated commercial system. --- ## Regional Analysis # CHAPTER 6 - Regional Analysis Indonesia ranks first by generic pharmaceutical market size among the selected Southeast Asian peers, supported by the region’s largest insured population and a 219-manufacturer finished-dose base. Its scale advantage exceeds Vietnam, the next-largest peer, while forecast growth remains competitive rather than the fastest in the group. ### KPI Summary * Focus Country Ranking: **1st** * Focus Country Market Size: **USD 4,400 Mn (2025)** * Focus Country CAGR (2026-2031): **7.4%** | Country | Market Size (USD Mn, 2025) | CAGR (%, 2026-2031) | Adult Diabetes Prevalence (%, 2024) | Primary Generic Policy Mechanism | | --- | --- | --- | --- | --- | | Indonesia | 4,400 | 7.4% | 11.3% | JKN formulary and e-catalogue procurement | | Vietnam | 3,200 | 5.0% | - | Health insurance tender preference | | Philippines | 2,400 | 8.5% | 7.5% | Generics Act and Universal Health Care | | Thailand | 2,000 | 6.7% | 10.2% | Universal Coverage procurement | | Malaysia | 1,300 | 6.2% | 21.1% | National Medicines Policy substitution | ### Market Position Indonesia ranks **1st** among five selected peers with **USD 4,400 Mn** in 2025, ahead of Vietnam at USD 3,200 Mn, reflecting its substantially larger insured demand pool. ### Growth Advantage Indonesia’s **7.4%** forecast CAGR is above Vietnam’s modeled 5.0% and Malaysia’s 6.2%, but below the Philippines at 8.5%, positioning Indonesia as a high-scale, mid-to-upper growth market. ### Competitive Strengths Indonesia combines **282.7 million JKN participants**, **219 finished-dose manufacturers**, and **7 biosimilar producers**, creating peer-leading demand depth, manufacturing breadth, and policy-supported procurement access. --- ## Growth Drivers # CHAPTER 7 - Growth Drivers, Challenges & Opportunities Comprehensive analysis of key factors shaping the Indonesia Generic Pharmaceuticals Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments. ## Growth Drivers ### JKN Coverage and High-Frequency Healthcare Utilization Near-universal insurance creates recurring generic demand, with **282.7 million participants (2025, Indonesia)** covered by JKN. * JKN generated **725.3 million service uses (2025, Indonesia)**, creating a large prescription and refill base for essential generics across primary and referral care. Manufacturers with formulary breadth and tender reliability capture the strongest recurring volume. * The system worked through **23,770 primary facilities and 3,194 referral facilities (2025, Indonesia)**, extending demand beyond major hospitals. Distributors that can maintain regional fill rates gain strategic value as service intensity rises. * Public financing represented **58.5% of health expenditure (2024, Indonesia)**, reinforcing institutional purchasing power. Suppliers benefit when they align portfolios with reimbursement priorities, although disciplined cost structures remain necessary under public price ceilings. ### Rising Chronic Disease Treatment Requirements Long-duration treatment demand is expanding, with **20.4 million adults with diabetes (2024, Indonesia)** requiring sustained access to medicines. * Adult diabetes prevalence reached **11.3% (2024, Indonesia)**, supporting repeat demand for metformin, insulin, cardiovascular protection, and complication management. Portfolio owners with multi-therapy bundles can increase account value across hospitals and pharmacies. * Measured hypertension prevalence was **30.8% among adults aged 18+ (2023, Indonesia)**, creating a broad addressable base for antihypertensives and lipid-lowering generics. High adherence programs can differentiate otherwise commoditized molecules. * Only **8.6% of adults reported a prior hypertension diagnosis (2023, Indonesia)**, indicating a large diagnosis gap. Expanded screening can convert undetected disease into treatment demand, benefiting primary-care channels and chronic refill platforms. ### Domestic Manufacturing and Faster Regulatory Throughput Indonesia’s supply base includes **219 finished-dose manufacturers (2025, Indonesia)**, supporting broad local participation and product availability. * BPOM completed review of **915 generic renewals in under three months (2025, Indonesia)**, reducing continuity risk for high-use products. Faster regulatory resolution supports working-capital planning and lowers the probability of avoidable portfolio gaps. * Regulators issued **769 renewed licenses, equal to 84% of applications (2025, Indonesia)**, demonstrating that compliant dossiers can progress at scale. Companies with mature bioequivalence and quality systems gain a measurable time-to-market advantage. * The acceleration program involved **77 pharmaceutical companies (2024, Indonesia)**, showing broad industry engagement. Regulatory collaboration can improve submission quality and protect JKN supply, while still preserving strict rejection of insufficient evidence. --- ## Market Challenges ### Reimbursement and Procurement Price Misalignment Public buyers face material price gaps, with **more than half of assessed facilities above reimbursement ceilings (2024-2025, Indonesia)**. * Some procurement prices reached **up to 10 times claimable rates (2024-2025, Indonesia)**, directly pressuring hospital budgets and supplier payment cycles. Manufacturers must balance tender access with financially sustainable contract terms. * The assessment covered **25 facilities in 4 provinces (2024-2025, Indonesia)**, identifying fragmented purchasing pathways and credential constraints. Operators that improve e-catalogue execution and demand forecasting can reduce leakage and emergency procurement. * Only **64% of facilities reported availability above 80% (2024-2025, Indonesia)**, with shortages in insulin and other essential medicines. Poor availability creates lost sales, treatment disruption, and reputational risk for both providers and suppliers. ### Imported API Exposure and Limited Upstream Depth Generic production remains vulnerable because approximately **90% of pharmaceutical raw materials were imported (latest policy baseline, Indonesia)**. * Only **18 active pharmaceutical ingredient manufacturers (2025, Indonesia)** were recorded against 219 finished-dose manufacturers. This imbalance concentrates foreign-exchange and lead-time risk upstream, limiting margin control for local formulators. * The industrial policy target sought a **40% reduction in imported raw materials by 2026 (Indonesia)**, implying significant localization requirements. Execution depends on scale economics, validated suppliers, and willingness to redesign registered product sources. * Imported-input dependence was explicitly linked to stock disruption in the **2024-2025 medicine availability review (Indonesia)**. Dual sourcing and longer safety stocks can protect service levels but increase working capital and inventory obsolescence risk. ### Quality Compliance and Portfolio Renewal Risk Regulatory backlogs can remove products from supply, as **1,397 medicine licenses were reported expired (2024, Indonesia)**. * Expired licenses included **915 generic products linked to JKN, e-catalogue, or non-catalogue demand (2024, Indonesia)**. Portfolio interruption can transfer volume rapidly to compliant competitors and weaken hospital relationships. * BPOM declined or cancelled **146 applications, equal to 16% of reviewed renewals (2025, Indonesia)**, due to insufficient scientific or quality evidence. Strong analytical, bioequivalence, and pharmacopoeial capabilities are therefore commercial assets. * The review relied on **40 generic-drug evaluators (2025, Indonesia)**, highlighting the resource intensity of regulatory assessment. Submission planning, dossier standardization, and early deficiency resolution can materially shorten time at risk. --- ## Market Opportunities ### API and Pharmaceutical Input Localization Localization economics are improving, with **14,640 tons of annual pharmaceutical salt capacity (2025, Indonesia)** now certified. * A newly certified facility added **12,000 tons per year (2025, Indonesia)**, creating a monetizable supply opportunity in validated local inputs. Producers can capture import-substitution revenue and reduce customer lead times. * Indonesia had **3 certified pharmaceutical salt manufacturers (2025, Indonesia)**, leaving room for supplier diversification, contract manufacturing, and specialty-grade expansion. Investors benefit where local capacity meets BPOM quality requirements and customer change-control needs. * Only **18 API manufacturers (2025, Indonesia)** serve a much larger finished-dose base, so scale-up requires process technology, long-term offtake, and regulatory support for source changes. Successful localization can improve supply resilience and margin visibility. ### Digital Refill and Omnichannel Pharmacy Models Digital distribution has a broad foundation, with **79.5% internet penetration (2024, Indonesia)** supporting online medicine discovery and refills. * Indonesia had approximately **221.6 million internet users (2024, Indonesia)**, enabling large-scale patient engagement. Pharmacy platforms can monetize refill reminders, delivery, adherence services, and manufacturer-sponsored education within regulatory boundaries. * Java internet penetration reached **83.64% (2024, Indonesia)**, supporting attractive unit economics in dense metropolitan corridors. Omnichannel operators benefit from shorter delivery routes and higher repeat-order potential. * Sulawesi penetration was lower at **68.35% (2024, Indonesia)**, showing that digital expansion requires regional logistics, trust, and payment adaptation. Operators that combine local pharmacy inventory with platform demand can unlock underserved markets. ### Biosimilars and Differentiated Chronic-Care Generics Differentiated portfolios have room to scale, with only **7 biosimilar manufacturers (2025, Indonesia)** in the certified production base. * The **20.4 million adult diabetes cases (2024, Indonesia)** support insulin biosimilars, combination therapies, and adherence programs. Manufacturers with clinical, regulatory, and cold-chain capabilities can access higher-value chronic-care profit pools. * Measured hypertension affected **30.8% of adults aged 18+ (2023, Indonesia)**, creating demand for differentiated fixed-dose combinations and long-duration packs. Pharmacy and provider partnerships can improve persistence while building brand trust around generic quality. * Out-of-pocket spending fell to **28.3% of total health expenditure (2024, Indonesia)**, increasing the strategic importance of reimbursed pathways. Suppliers must secure formulary access, evidence quality, and hospital economics for specialty generics to scale. --- --- ## Competitive Landscape # CHAPTER 8 - Competitive Landscape Overview Competition is fragmented across large domestic groups and specialist manufacturers; regulatory compliance, tender access, portfolio breadth, and distribution reach create higher barriers than basic formulation capability alone. * **Key players:** 10 * **New Entrants (last 5 yrs):** - ### Company Profiles (Top 10 Players) | Company Name | Market Share | Headquarters | Founding Year | Core Market Focus | | --- | --- | --- | --- | --- | | PT Kalbe Farma Tbk | - | Jakarta, Indonesia | 1966 | Unbranded and branded generics across chronic and acute therapies | | PT Dexa Medica | - | Tangerang, Indonesia | 1969 | Branded generics, specialty generics, and prescription products | | PT Sanbe Farma | - | Bandung, Indonesia | 1975 | Oral solids, sterile injectables, and hospital-focused medicines | | PT Kimia Farma Tbk | - | Jakarta, Indonesia | 1817 | JKN generics, manufacturing, distribution, and national pharmacy access | | PT Darya-Varia Laboratoria Tbk | - | Jakarta, Indonesia | 1976 | Prescription generics and consumer healthcare products | | PT Indofarma Tbk | - | Bekasi, Indonesia | 1918 | Public-sector, essential-medicine, and generic pharmaceutical supply | | PT Phapros Tbk | - | Jakarta, Indonesia | 1954 | Branded generics and hospital prescription products | | PT SOHO Global Health Tbk | - | Jakarta, Indonesia | 1946 | Prescription products, healthcare distribution, and commercial access | | PT Novell Pharmaceutical Laboratories | - | Bogor, Indonesia | 1998 | Specialty, branded generic, and hospital products | | PT Otto Pharmaceutical Industries | - | Bandung, Indonesia | 1963 | Generic oral solids, liquids, and injectable medicines | The report provides detailed cross-comparison of key players across 4 performance parameters to identify competitive strengths and weaknesses. ### Top 4 Cross-Comparison KPIs * BPOM Registration Renewal Rate * Generic Portfolio Breadth * Indonesia Generic Revenue Growth * EBITDA Margin ### Analysis Covered * **Market Share Analysis:** Benchmarks company scale, channel reach, therapy concentration, and competitive positioning. * **Cross Comparison Matrix:** Compares regulatory execution, portfolio depth, growth, margins, and operational resilience. * **SWOT Analysis:** Identifies company strengths, vulnerabilities, opportunities, threats, and strategic response priorities. * **Pricing Strategy Analysis:** Evaluates tender pricing, retail premiums, portfolio mix, and margin discipline. * **Company Profiles:** Reviews capabilities, operating focus, geographic reach, ownership, and strategic positioning. --- --- ## Key Stakeholders # CHAPTER 10 - Key Target Audience Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning. * **Investors:** market CAGR, portfolio mix, margins, regulatory risk * **Corporates:** tender access, production utilization, pricing, channel gaps * **Government:** medicine access, formulary compliance, API localization, quality * **Operators:** registration velocity, stock availability, service levels, distribution * **Financial institutions:** working capital, capex, covenants, cash flow resilience ### What You'll Gain * Market sizing and trajectory * Policy and compliance mapping * Supply exposure indicators * Segment structure and levers * Competitive landscape shortlist * CEO-grade risk priorities --- --- ## Research Methodology # CHAPTER 11 - Research Methodology ### Phase 1: Approach #### Desk Research * Reviewed BPOM generic registration records * Mapped JKN formulary procurement structure * Analyzed pharmaceutical manufacturing facility capacity * Benchmarked chronic-disease treatment demand indicators #### Primary Research * Interviewed pharmaceutical commercial directors * Consulted regulatory affairs department heads * Engaged hospital procurement and pharmacy leaders * Surveyed wholesalers and retail pharmacy managers #### Validation and Triangulation * Validated through 340 stakeholder responses * Reconciled manufacturer and channel estimates * Cross-checked volume and value growth * Tested forecast assumptions across scenarios ### Phase 2: Market Size Estimation #### Top-Down Assessment * Indonesia pharmaceutical spending and generic penetration * Therapy demand across public and private care * JKN, BPOM, health accounts, and disease indicators #### Bottom-Up Modeling * Manufacturer portfolio and channel sales benchmarks * Generic pack pricing and tender realization * Prescription volume multiplied by net realized price #### Forecasting and Scenario Analysis * JKN utilization, chronic burden, and product mix * API localization, reimbursement, and registration scenarios * Baseline, optimistic, and constrained projections through 2031 ### Phase 3: Primary Research Coverage #### Scope Item / Segments Coverage spans the full value chain of the Indonesia Generic Pharmaceuticals Market from upstream inputs and manufacturing to institutional procurement, pharmacy distribution, and chronic-care use. * Generic Manufacturers and API Suppliers * Hospital and JKN Procurement Stakeholders * Pharmacy and Distribution Channel Operators * Prescribers and Chronic-Care End Users #### Sample Size A total of 340 respondents were engaged across four value-chain segments to ensure statistically robust coverage of the Indonesia Generic Pharmaceuticals Market. * Generic Manufacturers and API Suppliers - 100 respondents (Manufacturing Directors, API Sourcing Heads) * Hospital and JKN Procurement Stakeholders - 90 respondents (Hospital Procurement Directors, Formulary Pharmacists) * Pharmacy and Distribution Channel Operators - 80 respondents (Wholesale Distribution Managers, Retail Pharmacy Managers) * Prescribers and Chronic-Care End Users - 70 respondents (General Practitioners, Chronic-Care Patients) #### Validation and Triangulation Validation compared commercial, operational, procurement, and user evidence across the Indonesia Generic Pharmaceuticals Market value chain. * Manufacturer volumes matched channel throughput patterns * API inputs reconciled with finished-dose output * Operational responses checked against strategic interviews * Market totals tested against prescription economics --- ## Frequently Asked Questions # CHAPTER 12 - FAQs #### Q: What is the size of the Indonesia Generic Pharmaceuticals Market in 2025? **A:** The Indonesia Generic Pharmaceuticals Market is worth USD 4,400 million in 2025. This estimate covers domestic sales of off-patent small-molecule generics and biosimilars through public and private channels, while excluding originator brands and export revenue. Demand is anchored by 282.7 million JKN participants and broad use of formulary medicines across primary and referral care. The market’s scale also reflects a mature substitution base, with generics representing the majority of pharmaceutical volume and domestic manufacturers supplying both tender-driven and retail demand. **Data used:** USD 4,400 million market value in 2025; 282.7 million JKN participants in 2025. **So what:** Market entry plans should prioritize reimbursed high-volume products before expanding into differentiated specialty categories. #### Q: How fast will the Indonesia Generic Pharmaceuticals Market grow through 2031? **A:** The market is projected to grow at a 7.4% CAGR from 2026 to 2031, reaching USD 6,750 million by 2031. Growth is expected to remain structurally supported by chronic-disease treatment, near-universal JKN coverage, and gradual expansion of biosimilars, complex generics, and digital refill channels. The forecast is slightly below the 7.6% historical CAGR recorded during 2020-2025, reflecting a larger base and continued public-sector price discipline. Value growth should remain faster than unit growth as therapy mix shifts toward higher-complexity formulations and hospital products. **Data used:** 7.4% forecast CAGR during 2026-2031; USD 6,750 million projected value in 2031. **So what:** Investors should underwrite portfolio mix and tender economics, not rely solely on unit-volume expansion. #### Q: Where will profit pools shift within Indonesia generic pharmaceuticals? **A:** Profit pools are likely to move toward specialty generics, complex formulations, biosimilars, chronic-care bundles, and integrated distribution services. Commodity oral solids will remain the volume foundation, but aggressive tender pricing and broad supplier availability constrain margins. By contrast, technically demanding injectables, insulin biosimilars, fixed-dose combinations, and adherence-enabled refill models require stronger regulatory, clinical, or operational capabilities. Indonesia already has seven biosimilar manufacturers, while online pharmacy share is modeled to rise from 3.0% in 2025 to 8.0% in 2031, supporting differentiated routes to patients. **Data used:** 7 biosimilar manufacturers in 2025; online pharmacy share modeled at 3.0% in 2025 and 8.0% in 2031. **So what:** Companies should allocate capital to capabilities that create defensibility beyond basic molecule availability. #### Q: What is the largest operating risk in the market? **A:** The largest operating risk is the combination of reimbursement-price mismatch and imported API dependence. In a 2024-2025 review, more than half of assessed facilities procured medicines above reimbursement ceilings, with some prices reaching ten times claimable rates. At the same time, approximately 90% of pharmaceutical raw materials have historically been imported, exposing manufacturers to currency, freight, and lead-time volatility. These pressures can compress margins, delay hospital supply, and increase working capital even when prescription demand remains strong. **Data used:** More than half of assessed facilities above reimbursement ceilings in 2024-2025; approximately 90% imported raw-material dependence. **So what:** Winning operators need disciplined contract selection, dual sourcing, and tighter receivables and inventory controls. #### Q: How does Indonesia compare with nearby generic pharmaceutical markets? **A:** Indonesia is the largest among the five selected Southeast Asian peer markets, at USD 4,400 million in 2025. Vietnam follows at USD 3,200 million, while the Philippines, Thailand, and Malaysia are smaller at USD 2,400 million, USD 2,000 million, and USD 1,300 million, respectively. Indonesia’s 7.4% forecast CAGR is above modeled growth for Vietnam and Malaysia but below the Philippines. Its competitive advantage comes from exceptional JKN scale and a 219-company finished-dose manufacturing base, although upstream API depth remains limited. **Data used:** Indonesia rank: 1st among five peers in 2025; 219 finished-dose manufacturers in 2025. **So what:** Regional strategies should treat Indonesia as the scale anchor and use peers for selective portfolio or export diversification. #### Q: Which demand driver matters most for long-term growth? **A:** Chronic disease is the most durable demand driver because it generates repeat prescriptions across primary care, hospitals, and retail channels. Indonesia had 20.4 million adults with diabetes in 2024, representing 11.3% adult prevalence, while measured hypertension affected 30.8% of adults aged 18 and older in 2023. The large diagnosis gap in hypertension suggests further treatment conversion as screening improves. This favors broad cardiovascular, endocrine, and metabolic portfolios, especially where companies support adherence and reliable regional replenishment. **Data used:** 20.4 million adults with diabetes in 2024; 30.8% measured hypertension prevalence in adults during 2023. **So what:** Portfolio design should prioritize refill-intensive therapies with multi-year patient value and broad formulary relevance. #### Q: What capabilities will define competitive advantage by 2031? **A:** Competitive advantage will depend on regulatory execution, product complexity, supply resilience, and channel integration. BPOM completed 915 generic renewals in under three months, but 16% of applications were not approved, demonstrating that dossier and quality capability directly affect commercial continuity. Companies also need local or diversified API sourcing, reliable JKN tender fulfillment, and digital access to chronic patients. The strongest platforms will combine simple-generic scale with complex products, hospital relationships, retail reach, and data-enabled inventory planning rather than competing only on price. **Data used:** 915 generic renewals reviewed in 2025; 16% of applications not approved. **So what:** Management teams should measure regulatory renewal rate, portfolio breadth, service levels, and cash conversion together. --- ## Table of Contents # Table of Contents ### Market Report Structure Comprehensive coverage across three strategic phases; Market Assessment, Go-To-Market Strategy, and Survey; delivering end-to-end insights from market analysis and execution roadmap to customer demand validation. ## Market Assessment Phase Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts. ### 1. Executive Summary and Approach ### 2. Indonesia Generic Pharmaceuticals Market Overview #### 2.1 Key Insights and Strategic Recommendations #### 2.2 Indonesia Generic Pharmaceuticals Market Overview #### 2.3 Definition and Scope #### 2.4 Evolution of Market Ecosystem #### 2.5 Timeline of Key Regulatory Milestones #### 2.6 Value Chain and Stakeholder Mapping #### 2.7 Business Cycle Analysis #### 2.8 Policy and Incentive Landscape ### 3. Indonesia Generic Pharmaceuticals Market Analysis #### 3.1 Growth Drivers ##### 3.1.1 JKN Coverage and High-Frequency Healthcare Utilization ##### 3.1.2 Rising Chronic Disease Treatment Requirements ##### 3.1.3 Domestic Manufacturing and Faster Regulatory Throughput #### 3.2 Market Challenges ##### 3.2.1 Reimbursement and Procurement Price Misalignment ##### 3.2.2 Imported API Exposure and Limited Upstream Depth ##### 3.2.3 Quality Compliance and Portfolio Renewal Risk #### 3.3 Market Opportunities ##### 3.3.1 API and Pharmaceutical Input Localization ##### 3.3.2 Digital Refill and Omnichannel Pharmacy Models ##### 3.3.3 Biosimilars and Differentiated Chronic-Care Generics #### 3.4 Market Trends ##### 3.4.1 Simple Generic Volume Dominance ##### 3.4.2 Chronic Therapy Mix Expansion ##### 3.4.3 Online Pharmacy Share Expansion ##### 3.4.4 Biosimilar Capability Build-Up #### 3.5 Government Regulation ##### 3.5.1 JKN Formulary Prioritization ##### 3.5.2 BPOM Product Registration Renewal ##### 3.5.3 CPOB Quality Standards ##### 3.5.4 E-Catalogue Procurement and Price Ceilings ### 4. SWOT Analysis ### 5. Stakeholder Analysis ### 6. Porter's Five Forces Analysis ### 7. Indonesia Generic Pharmaceuticals Market Historical Market Size #### 7.1 By Value #### 7.2 By Volume #### 7.3 By Average Selling Price ### 8. Indonesia Generic Pharmaceuticals Market Segmentation #### 8.1 Product Type ##### 8.1.1 Simple Generics ##### 8.1.2 Specialty Generics ##### 8.1.3 Complex Generics ##### 8.1.4 Biosimilars #### 8.2 Therapeutic Area ##### 8.2.1 Cardiovascular ##### 8.2.2 Anti-Infectives ##### 8.2.3 Endocrine and Metabolic ##### 8.2.4 Other Therapeutic Areas #### 8.3 Formulation and Drug Delivery ##### 8.3.1 Oral ##### 8.3.2 Injectables ##### 8.3.3 Dermal and Topical ##### 8.3.4 Inhalation #### 8.4 Care Setting ##### 8.4.1 Hospitals ##### 8.4.2 Primary Care Facilities ##### 8.4.3 Specialist Clinics ##### 8.4.4 Home-Based Care #### 8.5 End User ##### 8.5.1 Public Health Providers ##### 8.5.2 Private Hospitals and Clinics ##### 8.5.3 Retail Pharmacies ##### 8.5.4 Patients and Caregivers #### 8.6 Distribution Channel ##### 8.6.1 Hospital Pharmacies ##### 8.6.2 Retail Pharmacies ##### 8.6.3 Government E-Procurement ##### 8.6.4 Online Pharmacies #### 8.7 Geography ##### 8.7.1 Java ##### 8.7.2 Sumatra ##### 8.7.3 Kalimantan ##### 8.7.4 Eastern Indonesia ### 9. Indonesia Generic Pharmaceuticals Market Competitive Analysis #### 9.1 Market Share of Key Players (Micro, Small, Medium, Large Enterprises) #### 9.2 Cross Comparison of Key Players ##### 9.2.1 Company Name ##### 9.2.2 Group Size (Large, Medium, or Small as per industry convention) ##### 9.2.3 BPOM Registration Renewal Rate ##### 9.2.4 Generic Portfolio Breadth ##### 9.2.5 Indonesia Generic Revenue Growth ##### 9.2.6 EBITDA Margin #### 9.3 SWOT Analysis of Top Players #### 9.4 Pricing Analysis #### 9.5 Detailed Profile of Major Companies ##### 9.5.1 PT Kalbe Farma Tbk ##### 9.5.2 PT Dexa Medica ##### 9.5.3 PT Sanbe Farma ##### 9.5.4 PT Kimia Farma Tbk ##### 9.5.5 PT Darya-Varia Laboratoria Tbk ##### 9.5.6 PT Indofarma Tbk ##### 9.5.7 PT Phapros Tbk ##### 9.5.8 PT SOHO Global Health Tbk ##### 9.5.9 PT Novell Pharmaceutical Laboratories ##### 9.5.10 PT Otto Pharmaceutical Industries ### 10. Indonesia Generic Pharmaceuticals Market End-User Analysis #### 10.1 Procurement Behavior of Key End-Users ##### 10.1.1 JKN Tender Participation ##### 10.1.2 Hospital Formulary Selection ##### 10.1.3 Retail Pharmacy Replenishment ##### 10.1.4 Online Refill Procurement #### 10.2 Corporate Spend Patterns ##### 10.2.1 Public Hospital Medicine Budgets ##### 10.2.2 Private Hospital Generic Mix ##### 10.2.3 Wholesaler Working Capital Cycles ##### 10.2.4 Pharmacy Inventory Turnover #### 10.3 Pain Point Analysis by End-User Category ##### 10.3.1 Hospital Reimbursement Gaps ##### 10.3.2 Primary Care Stock Availability ##### 10.3.3 Retail Substitution Confidence ##### 10.3.4 Patient Adherence Barriers #### 10.4 User Readiness for Adoption ##### 10.4.1 Prescriber Generic Confidence ##### 10.4.2 Pharmacist Substitution Capability ##### 10.4.3 Patient Digital Refill Readiness ##### 10.4.4 Institutional Biosimilar Readiness #### 10.5 Post-Deployment ROI and Use Case Expansion ##### 10.5.1 Tender Win Economics ##### 10.5.2 Portfolio Cross-Selling ROI ##### 10.5.3 Digital Refill Retention ##### 10.5.4 Regional Distribution Expansion ### 11. Indonesia Generic Pharmaceuticals Market Future Market Size #### 11.1 By Value #### 11.2 By Volume #### 11.3 By Average Selling Price ## Go-To-Market Strategy Phase Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook. ### 1. Whitespace Analysis and Business Model Canvas #### 1.1 Complex Generic Portfolio Gaps #### 1.2 Biosimilar Access Opportunities #### 1.3 Eastern Indonesia Supply Whitespace #### 1.4 Chronic Refill Service Models ### 2. Marketing and Positioning Recommendations #### 2.1 Quality-Led Generic Positioning #### 2.2 JKN Value Proposition #### 2.3 Prescriber Evidence Programs #### 2.4 Patient Adherence Messaging ### 3. Distribution Plan #### 3.1 Hospital Tender Coverage #### 3.2 Retail Pharmacy Network Design #### 3.3 Wholesaler Territory Allocation #### 3.4 Online Pharmacy Integration ### 4. Channel and Pricing Gaps #### 4.1 E-Catalogue Price Sustainability #### 4.2 Private Hospital Premium Gaps #### 4.3 Retail Pack-Size Optimization #### 4.4 Digital Fulfillment Economics ### 5. Unmet Demand and Latent Needs #### 5.1 Reliable Insulin Availability #### 5.2 Complex Injectable Access #### 5.3 Rural Chronic Refill Coverage #### 5.4 Affordable Specialty Therapies ### 6. Customer Relationship #### 6.1 Hospital Key-Account Governance #### 6.2 Pharmacist Education Programs #### 6.3 Prescriber Medical Engagement #### 6.4 Patient Refill Support ### 7. Value Proposition #### 7.1 Affordable Quality Assurance #### 7.2 Reliable National Supply #### 7.3 Differentiated Therapy Breadth #### 7.4 Integrated Omnichannel Access ### 8. Key Activities #### 8.1 BPOM Dossier Management #### 8.2 Tender and Formulary Access #### 8.3 Demand and Inventory Planning #### 8.4 Distributor Performance Management ### 9. Entry Strategy Evaluation #### 9.1 Domestic Market Entry Strategy ##### 9.1.1 Local Registration and Licensing ##### 9.1.2 JKN Formulary Access ##### 9.1.3 Domestic Manufacturing Partnership ##### 9.1.4 National Distribution Build-Out #### 9.2 Export Entry Strategy ##### 9.2.1 ASEAN Registration Pathways ##### 9.2.2 Regional Distributor Selection ##### 9.2.3 Export Portfolio Prioritization ##### 9.2.4 Cross-Border Quality Documentation ### 10. Entry Mode Assessment #### 10.1 Greenfield Manufacturing #### 10.2 Contract Manufacturing #### 10.3 Joint Venture Partnership #### 10.4 Commercial Licensing ### 11. Capital and Timeline Estimation #### 11.1 Registration Investment #### 11.2 Manufacturing and Validation Capex #### 11.3 Working Capital Requirement #### 11.4 Commercial Launch Timeline ### 12. Control vs Risk Trade-Off #### 12.1 Portfolio Control #### 12.2 Quality and Compliance Risk #### 12.3 Channel Dependency #### 12.4 Reimbursement Exposure ### 13. Profitability Outlook #### 13.1 Simple Generic Margin Outlook #### 13.2 Specialty Generic Profit Pools #### 13.3 Tender Cash Conversion #### 13.4 Biosimilar Return Potential ### 14. Potential Partner List #### 14.1 Domestic Manufacturers #### 14.2 API and Excipient Suppliers #### 14.3 National Wholesalers #### 14.4 Hospital and Pharmacy Networks ### 15. Execution Roadmap #### 15.1 Phased Plan for Market Entry ##### 15.1.1 Market Setup ##### 15.1.2 Market Entry ##### 15.1.3 Growth Acceleration ##### 15.1.4 Scale and Stabilize #### 15.2 Key Activities and Milestones ##### 15.2.1 Complete Priority Product Registrations ##### 15.2.2 Secure Initial Formulary and Tender Access ##### 15.2.3 Expand Pharmacy and Distributor Coverage ##### 15.2.4 Launch Differentiated Chronic Portfolio ## Survey Phase Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers. ### 1. Research Design and Sample Architecture #### 1.1 Research Objectives and Scope #### 1.2 Sample Size Rationale and Representation #### 1.3 Customer Cohort Definitions #### 1.4 Geographic Coverage, Priority Metros and Tier 2/3 Cities ### 2. Data Collection Methodology #### 2.1 Structured Interview Framework ##### 2.1.1 Interview Guide and Question Design ##### 2.1.2 Respondent Recruitment and Screening Criteria ##### 2.1.3 Interview Execution and Quality Control ##### 2.1.4 Qualitative Coding and Insight Extraction #### 2.2 Online Survey Design ##### 2.2.1 Survey Instrument and Attribute Coverage ##### 2.2.2 Platform Selection and Distribution Channels ##### 2.2.3 Response Validation and Data Cleaning ##### 2.2.4 Statistical Significance and Margin of Error ### 3. Customer Cohort Profiles #### 3.1 Cohort 1, Generic Manufacturers and API Suppliers ##### 3.1.1 Cohort Definition and Size ##### 3.1.2 Key Demand Attributes ##### 3.1.3 Purchase Decision Drivers ##### 3.1.4 Represented Sample Size and Geographic Distribution #### 3.2 Cohort 2, Hospital and JKN Procurement Stakeholders ##### 3.2.1 Cohort Definition and Size ##### 3.2.2 Key Demand Attributes ##### 3.2.3 Purchase Decision Drivers ##### 3.2.4 Represented Sample Size and Geographic Distribution #### 3.3 Cohort 3, Pharmacy and Distribution Channel Operators ##### 3.3.1 Cohort Definition and Size ##### 3.3.2 Key Demand Attributes ##### 3.3.3 Purchase Decision Drivers ##### 3.3.4 Represented Sample Size and Geographic Distribution #### 3.4 Cohort 4, Prescribers and Chronic-Care End Users ##### 3.4.1 Cohort Definition and Size ##### 3.4.2 Key Demand Attributes ##### 3.4.3 Purchase Decision Drivers ##### 3.4.4 Represented Sample Size and Geographic Distribution ### 4. Demand Attributes Analysis #### 4.1 Macroeconomic and Sectoral Growth Influences on Demand ##### 4.1.1 Health Financing and JKN Linkages ##### 4.1.2 Chronic Disease Burden Impact ##### 4.1.3 Public Procurement Cycles ##### 4.1.4 Import Dependency on Pharmaceutical Inputs #### 4.2 End-User Behavior and Consumption Patterns ##### 4.2.1 Prescription and Refill Frequency ##### 4.2.2 Therapy Duration and Adherence ##### 4.2.3 Brand Loyalty vs Price Sensitivity ##### 4.2.4 Switching Triggers and Retention Factors #### 4.3 Pricing Perception and Value Assessment ##### 4.3.1 Willingness to Pay Across Channels ##### 4.3.2 Originator and Generic Price Benchmarking ##### 4.3.3 Regional Pricing Disparities ##### 4.3.4 Total Treatment Cost Perception #### 4.4 Quality, Safety, and Compliance Expectations ##### 4.4.1 BPOM Registration Requirements ##### 4.4.2 Bioequivalence and CPOB Confidence ##### 4.4.3 Domestic vs Imported Product Perception ##### 4.4.4 Pharmacovigilance and Support Expectations #### 4.5 Cultural, Regional, and Contextual Demand Factors ##### 4.5.1 Regional Healthcare Demand Hotspots ##### 4.5.2 Prescriber and Pharmacist Influence ##### 4.5.3 Peer and Professional Association Impact ##### 4.5.4 Digital Adoption and E-Procurement Readiness #### 4.6 Marketing, Awareness, and Channel Influence ##### 4.6.1 Medical Education and Industry Events ##### 4.6.2 Role of Digital Health Platforms ##### 4.6.3 Distributor and Pharmacy Influence ##### 4.6.4 Hospital and Prescriber Partnership Impact ### 5. Unmet Needs and Latent Demand Signals #### 5.1 Identified Gaps Between Current Supply and User Expectations #### 5.2 Latent Demand in Underpenetrated Segments #### 5.3 Willingness to Adopt New Formats or Technologies #### 5.4 Pain Points Surfaced Across Cohorts ### 6. Key Findings and Strategic Implications #### 6.1 Top Demand Drivers Ranked by Cohort #### 6.2 Barriers to Purchase and Adoption #### 6.3 High-Priority Customer Segments for Market Entry #### 6.4 Recommendations for Product, Pricing, and Channel Strategy ### Disclaimer ### Contact Us